(function(){ var content_array=["

关于<\/b>Novaliq <\/b><\/p> \n

Novaliq是一家生物制药公司，专注于基于全球首款无水眼滴技术EyeSol^{®<\/sup>的一流和同类最佳眼科疗法的开发和商业化。Novaliq提供行业领先的产品组合，以满足数百万眼病患者当今尚未得到满足的医疗需求。Novaliq GmbH总部位于德国海德堡，Novaliq Inc.在美国马萨诸塞州剑桥设有办事处。长期股东是生命和健康科学公司投资机构dievini Hopp BioTech holding GmbH & Co. KG。有关更多信息请见www.novaliq.com<\/a>。<\/p> \n}

[1] Agarwal P et al. Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs. International Journal of Pharmaceutics 538 (2018) 119-129<\/i> <\/p> \n

[2] Sheppard JD et al. A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase II\/III ESSENCE Study. Cornea, January 2021<\/span>, Publish Ahead of Print<\/i> https:\/\/doi.org\/10.1097\/ICO.0000000000002633 <\/i><\/p> \n

[3] Wirta DL et al. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease. Ophthalmology, Volume 126 (2019) 793-800<\/i> <\/p> \n

标志 - https:\/\/mma.prnasia.com\/media2\/1359866\/Novaliq_Logo.jpg?p=medium600<\/a><\/p>"]; $("#dvExtra").html(content_array[0]);})();